BODY COMPOSITION, PHYSICAL FUNCTION AND QUALITY OF LIFE IN HEALTHY MEN AND ACROSS DIFFERENT STAGES OF PROSTATE CANCER

Erik D. Hanson¹,²,⁷, Cameron K. Stopforth¹, Mohamdod Alzer¹, Jackson Carver¹, Alexander R. Lucas⁴,⁵, Young E. Whang²,³, Matthew I. Milowsky²,³, David B. Bartlett⁶, Michael R. Harrison⁶, Alan Hayes⁷,⁸, Rhonda L. Bitting⁴, Allison M. Deal², Anthony C. Hackney¹,⁹, Claudio L. Battaglini¹,²

¹Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, NC
²Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
³Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
⁴Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
⁵Virginia Commonwealth University, Richmond, VA
⁶Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC, USA
⁷Institute of Health and Sport, Victoria University, Melbourne, Vic, Australia
⁸Australian Institute for Musculoskeletal Science, Victoria University, Melbourne, Vic, Australia
⁹Department of Nutrition, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer (PC) has detrimental effects on physical function and quality of life (QoL), but the addition of androgen receptor signaling inhibitors (ARSI) on these outcomes is unclear.

PURPOSE: To compare body composition, physical function, and QoL across progressive stages of PC and non-cancer controls (CON).
**METHODS:** In men with hormone sensitive PC (HSPC, n=43) or metastatic castration-resistant PC (mCRPC, n=22) or CON (n=37), relative and absolute lean and fat mass, physical function (6m walk, chair stands, timed up and go [TUG], stair climb), and QoL were determined.

**RESULTS:** Relative body composition differed amongst all groups, along with ~39% greater absolute fat mass in mCRPC vs. CON. TUG and chair stands were ~71% and ~33% slower in mCRPC compared to both CON and HSPC, whereas stair climb was ~29% and 6m walk was ~18% slower in mCRPC vs. CON. Relative body composition was correlated with physical function (r=0.259–0.385). Clinically relevant differences for mCRPC were observed for overall QoL and several subscales vs. CON, although body composition and physical function did not influence QoL.

**CONCLUSIONS:** PC progression is associated with deteriorations in body composition and physical function. As ADT length was similar between groups, ARSI use for mCRPC likely contributed in part to these changes. Given the difficulties of improving lean mass during ADT, interventions that reduce adiposity may lessen the side effects of hormone therapy.

**Keywords**
androgen deprivation therapy; exercise oncology; activities of daily living; advanced prostate cancer

**INTRODUCTION**
Prostate cancer (PC) accounts for ~200 000 new cases annually in the United States alone, making it the most common non-dermatological tumor in men (1). Androgen deprivation therapy (ADT) reduces testosterone levels and slows tumor progression (2) but has adverse effects, including decreased lean and bone mass, increased fat mass (3–7) and reduced physical function (5, 8–11) and quality of life (QoL) (12–14). However, the effect of ADT in men with more advanced PC is not clearly defined.

With time, PC may progress to castration resistance (15) and metastasize to sites such as lymph nodes or bone (16), claiming the lives of ~33 000 men per year (1). Metastatic castration-resistant prostate cancer (mCRPC) often requires the addition of secondary hormonal therapies (17). Although abiraterone acetate and enzalutamide affect the androgen axis via different mechanisms, these androgen receptor signaling inhibitors (ARSI) delay tumor progression and improve survival outcomes (18, 19). However, there are additional side effects to be considered. Relative to a 1.2% decrease in lean mass from ADT (7), abiraterone reduced lean mass by 4.3% over ~6 mo while also increasing fat mass (20). Fall risk, hypertension and fatugue also increase with enzalutamide (18, 21, 22). While increased falls and fatigue are suggestive of poorer physical function, direct measures are lacking during mCRPC treatment. Moreover, ARSI may affect QoL in different ways. For example, among older men (>75y), QoL scores increased over 24 weeks with abiraterone while enzalutamide use resulted in greater proportions of men having clinically significant declines in functional and physical well-being (23). While QoL degradation occurred over time in both groups, scores were higher with lower self-reported pain when combining abiraterone with ADT vs. ADT alone (12).
With a lack of direct measures of body composition, physical function and QoL and few comparisons to men with less advanced PC, the true estimates of decline with mCRPC are poorly defined. As such, designing effective interventions is challenging as exercise oncology guidelines are generally written for localized disease (24, 25), primarily due to insufficient evidence in metastatic PC. However, metastatic PC has the highest 5y survival rates of the major cancer types (1) and ARSI increases overall survival (18, 19). Accordingly, this population may benefit greatly from therapies that target physical function and QoL. Consequently, the primary purpose of this study was to estimate differences in body composition, physical function, and QoL across progressive stages of PC and compared to non-cancer controls (CON). We also sought to determine if associations exist between body composition, physical function, and QoL. We hypothesized that ARSI use for mCRPC would exacerbate changes in body composition, physical function, and QoL vs. ADT alone and that increased fat mass and decreased lean mass would be associated with lower physical function and QoL.

**METHODS**

**Design**

This cross-sectional analysis included data from 4 previously published cohorts that assessed body composition, physical function, and QoL in prospective clinical trials or case-control studies (26–29). Men were recruited via local advertisements, PC support groups, and from referrals by physician collaborators.

**Participants**

Men with hormone sensitive PC (HSPC; n=42) were sedentary (no regular exercise except walking over past 6 mo) and were screened for conditions that would contraindicate exercise, including symptomatic cardiovascular or respiratory diseases, pain with exertion, Type 1 diabetes, history of bone fractures, or lack of medical clearance from their physician and included men on continuous ADT (n=28) in the form of luteinizing hormone releasing hormone agonists or anti-androgens for at least 3 mo with total testosterone levels <50ng/dL (26, 27, 29). The mCRPC cohort (n=22) met the same criteria as HSPC, were not currently on chemotherapy, and most were receiving ARSI treatments. Non-cancer controls (CON; n=37) met all inclusion criteria but had no PC history (28). All participants completed detailed medical histories questionnaires and provided written informed consent. Ethics committees at the University of Maryland, College Park, Peter MacCallum Cancer Centre, Victoria University, Western Health, and the University of North Carolina approved this project. The study was performed in accordance with the Declaration of Helsinki.

**Body Composition**

Body composition was assessed using whole-body dual-energy x-ray absorptiometry (Discovery W, model QDR 4500A Hologic, Waltham, MA, USA) to determine absolute and relative total fat and lean mass. All scans were performed and analyzed by the same certified densiometrist and the machine was calibrated daily.
Functional Tasks

All physical function tasks were explained, demonstrated, and participants performed a practice repetition. Two attempts were made (unless noted otherwise) with the fastest trial recorded.

**6m-Rapid Walk.**—Maximal walking speed was assessed by the time required to cover 6m as described previously (27, 28).

**5 Chair Stands.**—Using a straight-backed, armless chair (43 cm), participants fully stood without the use of their arms before returning to a seated position for a total of five repetitions (28). A subset of HSPC (n=19) completed as many chair stands as possible in 30s (27). Values were converted into the time per chair stand and multiplied by five to provide a comparable value. Only one set of chair stands were performed.

**Timed-Up-&-Go (TUG).**—Participants rose from a seated position (43cm chair) and walked around a cone 2.44m away and returned to a seated position.

**Stair Climb.**—Participants climbed a flight of 9 stairs (19 cm) as quickly as possible, as described previously (27, 28).

QoL Assessment

The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire was used to assess QoL. Clinical meaningful changes were determined as 6–10 points for FACT-P, 5–9 points for Trial Outcome Index (TOI), and 2–3 points for Prostate Cancer Subscale (PCS) (30).

Statistical Analysis

Chi-square and one-way ANOVA was used to compare groups with Tukey Post-Hoc test used to detect any within group differences. Data not meeting normality requirements (Kolmogorov-Smirnov) were log-transformed. Cohen’s d (d) effect sizes were calculated with trivial, small, medium and large effects being defined as <0.2, 0.2, 0.5 and 0.8, respectively. Data are mean (standard deviation) or ± 95% confidence intervals. Pearson’s correlation coefficients were used to assess relationships between all variables. Analyses were performed in SPSS v26 (IBM, Armonk, NY). Statistical significance was p<0.05 (two-sided).

RESULTS

Amongst the physical characteristics, there were trends for age (p=0.076) and race (p=0.058) differences between groups (Table 1). Prostatectomy and radiation frequency and ADT duration were similar between mCRPC and HSPC.

Body Composition

For absolute fat mass, mCRPC was 39% greater than CON [mean difference (MD)=8.6kg; 95%CI (2.0, 15.1kg); p=0.007; d=0.8; Fig. 1A]. Percent fat in mCRPC was greater than
HSPC [MD=4.8%; 95%CI (0.4, 9.2%); p=0.027; d=0.7] and CON [MD=8.3%; 95%CI (3.8, 12.8); p=0.001, d=1.5], with a trend for HSPC to be greater than CON [MD=3.5%; 95%CI (-0.03, 7.2); p=0.075, d=0.5; Fig. 1B]. Percent lean was lower in HSPC vs. CON [MD=2.8%; 95%CI (0.05, 5.6); p=0.045, d=0.6; Fig. 1B] while mCRPC was lower than both HSPC [MD=4.1%; 95%CI (0.81, 7.3); p=0.01, d=0.7] and CON [MD=6.9%; 95%CI (3.6, 10.2); p<0.001, d=1.3].

**Functional Tasks**

For TUG, mCRPC was 66% slower than CON [MD=4.0s; 95% CI (0.4, 7.6); p=0.025; d=0.6; Fig. 2A] and 76% slower than HSPC [MD=4.4s; 95%CI (0.3, 8.4); p=0.031; d=0.7]. mCRPC chair stands were also 37% slower than CON [MD=3.4s; 95%CI (1.0, 5.9); p=0.004; d=1.0; Fig. 2A] and 29% slower than HSPC [MD=2.8s; 95% CI (0.3, 5.3); p=0.023; d=0.8]. mCRPC stair climb was 29% slower than CON [MD=1.4s; 95%CI (0.3, 2.4); p=0.011; d=0.7; Fig 2B] and 28% slower than HSPC [MD=1.3s; 95%CI (0.1, 2.5); p=0.03; d=0.7]. mCRPC 6m walk was 18% slower than CON [MD=0.7s; 95%CI (0.01, 1.4); p=0.048; d=0.6; Fig. 2B] and trended to be 18% slower than HSPC [MD=0.7s; 95% CI (-0.07, 1.5); p=0.081; d=0.7; Fig. 2B].

**Quality of Life**

QoL analyses were only available on a subset of CON. Relative to CON, FACT-P was lower in mCRPC [MD=16.9; 95%CI (1.9, 31.9); p=0.024; d=1.2; Fig. 3A] with a trend for HSPC [MD=12.9; 95%CI (-0.3, 26.0); p=0.056; d=1.0]. mCRPC also had lower Trial Outcome Index [MD=13.0; 95%CI (1.8, 24.2); p=0.019, d=1.4] and for Prostate Cancer Subscale [MD=6.5; 95%CI (0.7, 12.3); p=0.024, d=1.0] vs. CON. HSPC showed trends for lower Trial Outcome Index [MD=8.6; 95%CI (-1.2, 18.4); p=0.096; d=1.0] and Prostate Cancer Subscale [MD=4.8; 95%CI (-0.3, 9.9); p=0.07, d=1.0] vs. CON. Large deficits in Physical Well-Being were present in both mCRPC [MD=3.7; 95%CI (0.6, 6.8); p=0.016; d=1.2; Fig 3B] and HSPC [MD=2.8; 95%CI (0.07, 5.6); p=0.044; d=1.2] vs. CON. Large differences in Social Well-Being were seen in HSPC only vs. CON [MD=4.1; 95%CI (0.9, 7.2); p=0.01, d=1.1].

**Correlations**

Lower % fat and higher % lean mass were correlated with higher functional capacity (Table 2). Lean mass % was also associated with Trail Outcome Index and a trend for FACT-P (p=0.069). Absolute fat mass was correlated with reduced physical function but to a lesser degree. Lean mass showed no relationship with physical function, nor was function associated with QoL.

**DISCUSSION**

Several key findings arose from this study. For the first time, we report differences in body composition across progressive stages of PC and provide direct assessments of functional deficits during advanced disease. mCRPC had poorer relative body composition, primarily due to greater absolute fat mass. Substantially lower physical function for mCRPC was observed compared to HSPC and CON. QoL was marginally lower in HSPC but large
differences were present in mCRPC. Collectively, these findings provide insight into the potential adverse effects of ARSI for metastatic PC. Interventions to minimize ADT-related side effects should limit gains in adipose tissue, as higher fat mass was associated with lower physical function.

**Body Composition**

With ~6 mo of ARSI treatment, mCRPC had absolute fat mass that was 8.6kg higher than CON and 3.9kg greater than HSPC, the latter difference having a large effect but was not statistically significant. Increases in fat mass have been well documented in ADT (5–8). In metastatic PC, 3 mo of ADT demonstrated only small increases in total fat mass (0.3–0.7 kg) during usual care (31, 32), although ARSI use was not reported. Using computed tomography, abiraterone decreased visceral and subcutaneous fat (20) while ADT showed no change (33) or even increased visceral fat mass (34). As our DXA measurements did not include visceral fat, we were unable to expand on these conflicting findings.

In contrast to longitudinal studies demonstrating reduced lean mass (3, 6, 7), HSPC and CON had similar levels. One possibility is that HSPC had greater lean mass prior to initiating ADT. As differences in fat mass account for only ~60% of the body mass discrepancy, we suggest that the 2.8% difference (Fig 1B) between groups in relative lean mass argues for this possibility. With abiraterone, abdominal muscle area was decreased by 3–4% after ~6 mo of treatment (20). Somewhat surprisingly, we report only small (d=0.2, −1.8%) to moderate (d=0.5, −5.3%) non-significant differences in absolute lean mass for mCRPC relative to CON and HSPC, respectively, although % lean mass shows large group differences and are similar to the declines in muscle area reported over time with abiraterone (20).

**Physical Function**

This is the first report, to our knowledge, to objectively quantify the loss of functionality in mCRPC relative to CON. Both longitudinal and cross-sectional studies show that physical function decreases with ADT (5, 8–11, 35). However, the response may be task specific (36) and appears consistent with the small (non-significant) differences observed between HSPC and CON. For mCRPC, the greatest deficit was in TUG. Due to a lack of comparative data in mCRPC, we compared our data to reference values where older men age 71–75 had a mean TUG time of 8.6 s (37). TUG times for HSPC and CON placed them in the 10th percentile and the lack of group differences was consistent with previous work (35). In contrast, mCRPC was in the 80th percentile and was similar to men age 81–85 years, suggesting mCRPC treatments contribute to ~10 years of age-related functional decline. Furthermore, the deficits in mCRPC vs. HSPC and CON both exceed minimal clinically important differences (35). Slower TUG times is somewhat predictive of falls risk (38) and may contribute to the elevated prevalence of falls with enzalutamide (39). Gait speed is also clinically relevant and while mCRPC gait speed was 20% slower than CON, the 1.3 m/sec we observed exceeds critical thresholds for independent living and mortality (40, 41).

Lower functional performance in mCRPC was greatest in tasks that involved overcoming gravity or change of direction, which may explain why 6m was less affected. As
such, negative alterations in body composition during ADT were hypothesized to impair performance. Indeed, relative lean and fat mass both correlate with physical function to a similar degree, albeit in opposite directions. Absolute fat mass appears to drive this, affecting both relative measures while also being linked to function directly. Surprisingly, absolute lean mass showed no relationship with functional performance but remains consistent with the lack of group differences (i.e. Fig 1A). In older adults, lean mass and strength are often correlated (42) and muscle strength and power are predictive of physical function (43). However, cancer cachexia highlights the disconnect between muscle mass and physical function (44), possibly due to the underlying assumption of a linear relationship. Despite significant hypertrophy following resistance training during ADT, only greater strength was associated with improved physical function (27), implying that neurological adaptations may be more prevalent. While maximal strength was measured in all cohorts, the use of slightly different machines prevented the inclusion of this outcome. Standardized strength assessments should be included in exercise oncology whenever possible (45). When combined with body composition analyses, neurological and lean mass alterations and their respective impact on muscle force and physical function can be teased out to improve exercise prescription during PC treatment.

Quality of Life

QoL was lower in mCRPC for FACT-P, TOI and PCS compared to CON with trends for reductions in HSPC, all of which were large, clinically relevant differences (30). Physical well-being was lower in both PC groups, which is consistent with ADT use for localized PC (13, 14) but also higher fat mass and reduced physical function. As FACT-P is not typically assessed in healthy men, only ~30% of CON completed this task and likely contributed to detecting only trends vs. HSPC. Normative data for FACT-G indicates all groups exceeded the means for healthy men and men with cancer, respectively (46). CON exceeded the mean by a full standard deviation (+17.5 points) while HSPC (+9.7 points) and mPC (+7.3 points) were only ~0.5 standard deviation higher. Irrespective of group, our cohort demonstrated high relative QoL scores that may be the result of the increased functionality and independence required to partake in exercise oncology trials.

In contrast to our hypothesis, the small differences between HSPC and mCRPC were not statistically nor clinically significant. Despite poorer body composition and physical function in mCRPC, neither factor was associated with the reduced QoL and suggests other factors are playing roles. One possibility is bone pain, as the addition of abiraterone vs. ADT alone slowed pain progression, fatigue and deterioration of QoL (12). The physiological and functional deficits and their lack of influence on QoL is attributed to the multi-factorial nature of QoL. We speculate that the ever-present effects of pain have more profound effects on QoL relative to more gradual declines in body composition and physical function that are less noticeable. While type of ARSI influences QoL (23), our abiraterone and enzalutamide samples sizes were too small to be analyzed separately but merit consideration in future studies.

This study had several limitations. The sample size for mCRPC was modest. While the same operator and make/model was used for body composition, data are from different machines.
Compared to HSPC, mCRPC tended to be older, were exposed to more treatments and likely had more comorbidities, and not all mCRPC received ARSI. While tempting to attribute group differences based on ARSI use, these factors could also influence the response.

In summary, PC progression is associated with deteriorations in body composition and poorer physical function. Clinically relevant deficits in QoL are observed in mCRPC and while the differences between HSPC and CON are non-significant, a concerning pattern is present. With recent approval to use ARSIs in hormone-sensitive metastatic PC (47), ARSI-related side effects may now present earlier in the treatment paradigm and potentially lead to greater loss of function and QoL over time. With higher survival rates in mCRPC relative to other advanced cancers, controlling adiposity should help maintain a high standard of living. With ADT attenuating muscle hypertrophy following resistance training (48), findings that extends to metastatic PC (31, 32) and animal models of ADT (49), interventions that increase neurological activation to promote strength gains with have potential to reverse functional declines during PC treatment.

Data Availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments

This study was supported by funding from the National Institute of Health grants AG018336, CA127784 and AG00268; the Claude D. Pepper Older Americans Independence Center (P30 AG028747); the Department of Veterans Affairs; Department of Industry, Innovation, and Science of Australia; Research Development grant scheme from Victoria University; the Oded Bar-Or International Scholar Award from the American College of Sports Medicine; and the Physical Activity and Cancer Survivorship pilot funding from the UNC Lineberger Comprehensive Cancer Center, Duke Cancer Institute and the Wake Forest Baptist Comprehensive Cancer Center.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. [PubMed: 31912902]
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44. [PubMed: 16014598]
3. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1):44–7. [PubMed: 18336606]
4. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–7. [PubMed: 16189261]
5. Levy ME, Perera S, van Londen GJ, Nelson JB, Clay CA, Greenspan SL. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology. 2008;71(4):735–9. [PubMed: 18279933]
6. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–6. [PubMed: 22649143]
7. van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol. 2008;68(2):172–7. [PubMed: 18706829]
8. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL. Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther. 2007;87(10):1325–33. [PubMed: 17684084]

9. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12(2):198–203. [PubMed: 18852703]

10. Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, et al. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016;24(5):2201–7. [PubMed: 26563183]

11. Joly F, Alibhai SM, Galica J, Park A, Yi QL, Wagner L, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176(6 Pt 1):2443–7. [PubMed: 17085125]

12. Chi KN, Protheroe A, Rodriguez-Antolin A, Facchini G, Suttman H, Matsubara N, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naïve prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19(2):194–206. [PubMed: 29326030]

13. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc. 2006;54(1):85–90. [PubMed: 16420202]

14. Gagliano-Juca T, Travison TG, Nguyen PL, Kantoff PW, Taplin ME, Kibel AS, et al. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018;55(2):307–17 e1. [PubMed: 28941963]

15. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501–11. [PubMed: 23752182]

16. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 2011;128(11):2545–61. [PubMed: 21365645]

17. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015;194(6):1537–47. [PubMed: 26196735]

18. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71(2):151–4. [PubMed: 27477525]

19. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. [PubMed: 21612468]

20. Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, et al. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer. 2013;109(2):325–31. [PubMed: 23807167]

21. Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, et al. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. Adv Ther. 2020;37(1):512–26. [PubMed: 31813087]

22. Ning YM, Brave M, Maher VE, Zhang L, Tang S, Sridhara R, et al. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2015;20(8):960–6. [PubMed: 26070917]

23. Khalaf DJ, Sunderland K, Egll BJ, Kollmannsberger CK, Ivanov N, Finch DL, et al. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. Eur Urol. 2019;75(6):940–7. [PubMed: 30591354]
24. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019;51(11):2375–90. [PubMed: 31626055]

25. Hayes SC, Newton RU, Spence RR, Galvao DA. The Exercise and Sports Science Australia position statement: Exercise medicine in cancer management. J Sci Med Sport. 2019;22(11):1175–99. [PubMed: 31277921]

26. Hanson ED, Sakkal S, Evans WS, Violet JA, Battaglini CL, McConell GK, et al. Altered stress hormone response following acute exercise during prostate cancer treatment. Scand J Med Sci Sports. 2018;28(8):1925–33. [PubMed: 29668082]

27. Hanson ED, Sheaff AK, Sood S, Ma L, Francis JD, Goldberg AP, et al. Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy. J Gerontol A Biol Sci Med Sci. 2013;68(4):490–8. [PubMed: 23089339]

28. Hanson ED, Srivatsan SR, Agrawal S, Menon KS, Delmonico MJ, Wang MQ, et al. Effects of strength training on physical function: influence of power, strength, and body composition. J Strength Cond Res. 2009;23(9):2627–37. [PubMed: 19910811]

29. Hanson ED, Sakkal S, Que S, Cho E, Spielmann G, Kadife E, et al. Natural killer cell mobilization and egress following acute exercise in men with prostate cancer. Exp Physiol. 2020;105(9):1524–39. [PubMed: 32715550]

30. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12(1):124–9. [PubMed: 18647260]

31. Cormie P, Newton RU, Spyr N, Joseph D, Taaffe DR, Galvao DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(4):328–35. [PubMed: 23917308]

32. Galvao DA, Taaffe DR, Spyr N, Cormie P, Joseph D, Chambers SK, et al. Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. Med Sci Sports Exerc. 2018;50(3):393–9. [PubMed: 29036016]

33. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603. [PubMed: 11836291]

34. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf). 2011;74(3):377–83. [PubMed: 21118287]

35. Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28(34):5038–45. [PubMed: 21041715]

36. Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012;14(2):204–21. [PubMed: 22367184]

37. Pondal M, del Ser T. Normative data and determinants for the timed “up and go” test in a population-based sample of elderly individuals without gait disturbances. J Geriatr Phys Ther. 2008;31(2):57–63. [PubMed: 19856551]

38. Barry E, Galvin R, Keogh C, Horgan F, Fahey T. Is the Timed Up and Go test a useful predictor of risk of falls in community dwelling older adults: a systematic review and meta-analysis. BMC Geriatr. 2014;14:14. [PubMed: 24484314]

39. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. [PubMed: 24881730]

40. Cesari M, Kritchevsky SB, Penninx BW, Nicklas BJ, Simonsick EM, Newman AB, et al. Prognostic value of usual gait speed in well-functioning older people—results from the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2005;53(10):1675–80. [PubMed: 16181165]
41. Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney E, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc. 2003;51(3):314–22. [PubMed: 12588574]

42. Chen L, Nelson DR, Zhao Y, Cui Z, Johnston JA. Relationship between muscle mass and muscle strength, and the impact of comorbidities: a population-based, cross-sectional study of older adults in the United States. BMC Geriatr. 2013;13:74. [PubMed: 23865675]

43. Bean JF, Leveille SG, Kiely DK, Bandinelli S, Guralnik JM, Ferrucci L. A comparison of leg power and leg strength within the InCHIANTI study: which influences mobility more? J Gerontol A Biol Sci Med Sci. 2003;58(8):728–33. [PubMed: 12902531]

44. Ramage MI, Skipworth RJE. The relationship between muscle mass and function in cancer cachexia: smoke and mirrors? Curr Opin Support Palliat Care. 2018;12(4):439–44. [PubMed: 30138131]

45. Hanson ED, Wagoner CW, Anderson T, Battaglini CL. The Independent Effects of Strength Training in Cancer Survivors: a Systematic Review. Curr Oncol Rep. 2016;18(5):31. [PubMed: 27025505]

46. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28(2):192–211. [PubMed: 15851773]

47. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700. [PubMed: 30987939]

48. Chen Z, Zhang Y, Lu C, Zeng H, Schumann M, Cheng S. Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Front Physiol. 2019;10:843. [PubMed: 31333495]

49. Hanson ED, Betik AC, Timpani CA, Tarle J, Zhang X, Hayes A. Testosterone suppression does not exacerbate disuse atrophy and impairs muscle recovery that is not rescued by high protein. J Appl Physiol (1985). 2020;129(1):5–16.
Figure 1.
Differences in A) absolute lean and fat mass and B) relative lean and fat mass in men with metastatic, castration-resistant (mCRPC, n=22) or hormone-sensitive prostate cancer (HSPC, n=42) and non-cancer controls (CON, n=37). Reported as mean ± 95% CI.
# P<0.05 vs, CON
† P<0.05 vs. HSPC
Figure 2.
Time to complete the A) timed up and go (TUG) and 5 chair stands and B) Stair climb and 6m walk in men with metastatic, castration-resistant (mCRPC, n=22) or hormone-sensitive prostate cancer (HSPC, n=17) and non-cancer controls (CON, n=27). Reported as mean ± 95% CI.

# P<0.05 vs, CON
† P<0.05 vs. HSPC
Figure 3.
Quality of life assessment scored by A) Prostate Cancer Subscale (PCS), Trial Outcome Index (TOI), and Functional Assessment of Cancer Therapy-Prostate (FACT-P), along with the B) Physical, Social, Emotional and Functional Well-Being subscales in men with metastatic, castration-resistant (mCRPC, n=18) or hormone-sensitive prostate cancer (HSPC, n=42) and non-cancer controls (CON, n=11).
Reported as mean ± 95% CI.
# P<0.05 vs. CON
## Table 1.
Physical characteristics of men with mCRPC, HSPC and non-cancer controls.

|                        | CON (n=37) | HSPC (n=42) | mCRPC (n=22) | P value |
|------------------------|------------|-------------|--------------|---------|
| Age (years)            | 69 (6)     | 67 (6)      | 72 (8)       | 0.076   |
| Height (cm)            | 174.9 (6.6)| 171.5 (17.0)| 175.0 (6.5)  | 0.324   |
| Mass (kg)              | 83.3 (13.7)| 90.7 (17.6) | 91.4 (18.8)  | 0.099   |
| Body mass index (kg/m²)| 27.1 (3.4) | 32.2 (14.2) | 29.8 (5.4)   | 0.101   |
| Race                   |            |             |              |         |
| Caucasian, n (%)       | 31 (84)    | 25 (59)     | 16 (73)      | 0.058   |
| African American, n (%)| 6 (16)     | 17 (41)     | 6 (27)       | 0.058   |
| Previous prostatectomy, n (%) | -     | 15 (36) | 11 (50)   | 0.269 |
| Previous radiotherapy, n (%) | -     | 22 (52) | 13 (59)   | 0.609 |
| ADT Duration (months)  | -          | 37 (38)     | 30 (34)      | 0.455   |
| ARSI Duration (months) | -          | -           | 6 (5)        | -       |
| Abiraterone, n (%)     | -          | -           | 9 (41)       | -       |
| Enzalutamide, n (%)    | -          | -           | 8 (36)       | -       |
| Previous chemotherapy, n (%) | -     | -           | 7 (33)      | -       |
| Time since chemotherapy (months) | - | -               | 16 (10) | - |

Data are mean (standard deviation) or n (%). Abbreviations: HSPC=hormone-sensitive prostate cancer, mCRPC=metastatic castration-resistant prostate cancer, CON=non-cancer controls, ADT=androgen deprivation therapy, LHRHa=luteinizing hormone releasing hormone agonists, ARSI=androgen receptor signaling inhibitors.
### Table 2.
Correlations between body composition, physical function and quality of life.

|       | Lean | Fat % | Lean % | 6m    | Chair | TUG  | Stair | PCS  | TOI  | FACT-P |
|-------|------|-------|--------|-------|-------|------|-------|------|------|---------|
| Fat   | 0.540** | 0.861** | -0.805** | 0.301* | 0.139 | 0.225 | 0.359** | -0.055 | -0.063 | -0.036  |
| Lean  | -    | 0.197* | -0.219  | 0.188 | -0.109 | 0.051 | 0.184 | -0.021 | -0.009 | -0.045  |
| Fat % | -    | -     | -0.765** | 0.267* | 0.264* | 0.259* | 0.318** | -0.122 | -0.130 | -0.115  |
| Lean %| -    | -     | -       | -0.305* | -0.230* | -0.321** | -0.385** | 0.190 | 0.246* | 0.222   |
| 6m    | -    | -     | -       | 0.364** | 0.766** | 0.844** | 0.118 | 0.121 | 0.171  |
| Chair | -    | -     | -       | -     | 0.103 | 0.342** | -0.065 | -0.043 | 0.032  |
| TUG   | -    | -     | -       | -     | -     | -     | 0.833** | 0.055 | 0.075 | 0.139   |
| Stair | -    | -     | -       | -     | -     | -     | -     | -0.152 | -0.081 | -0.012  |

Lean=absolute lean mass; Fat=absolute fat mass; Lean %; relative lean mass; Fat %; relative fat mass; Chair=5 chair stands; TUG=timed up and go; Stair=stair climb; PCS= Prostate Cancer Subscale; TOI=Trial Outcome Index; FACT-P=Functional Assessment of Cancer Therapy-Prostate

* p<0.05
** p<0.01